UP govt allows trial of coronavirus vaccine Covaxin in Lucknow, Gorakhpur
India | September 23, 2020 23:18 ISTThe Uttar Pradesh Government has allowed the phase-3 trial of the coronavirus vaccine 'Covaxin' in Lucknow and Gorakhpur on Wednesday.
The Uttar Pradesh Government has allowed the phase-3 trial of the coronavirus vaccine 'Covaxin' in Lucknow and Gorakhpur on Wednesday.
Coronavirus is raging like wildfire across the country, making India the second worst-hit country after the United States. But there is a bright spot amid this mayhem -- India's first indigenous coronavirus vaccine, Covaxin developed by Hyderabad-based Bharat Biotech, is likely to be launched in early 2021.
Coronavirus vaccine: At present, over 170 coronavirus vaccines are under development stage and out of them, there are 5-6 vaccines that are expected to be available for civilian use by the first quarter of 2021. Let's take a look at these coronavirus vaccines.
Hyderabad-based Bharat Biotech's coronavirus vaccine Covaxin has received Centre approval to conduct phase II clinical trials from September 7. Bharat Biotech secured the Centre’s nod to begin phase II trials of indigenous vaccine candidate Covaxin on September 3.
Preparations are underway at a hospital in Bhubaneswar for the commencement of the second phase of human clinical trial of 'Covaxin', India's indigenous COVID-19 vaccine, officials said.
The Bharat Biotech has got an approval to test administer its coronavirus experimental vaccine via skin. The Drug Controller General of India on Friday gave approval to the Hyderabad-based biotechnology company.
The Gauhati Medical College and Hospital (GMCH) has been selected for the second phase clinical testing of India's indigenously developed coronavirus vaccine, COVAXIN, Assam Health Minister Himanta Biswa Sarma said on Tuesday.
India's indigenously developed coronavirus vaccine, COVAXIN, has already shown successful results in phase 1 clinical trials. Now, for phase 2 clinical trials, Guwahati Medical College and Hospital (GMCH) has been chosen as one of the sites. Assam Health Minister Himanta Biswa Sarma on Friday has said that GMCH is set to be one of the centers for the phase 2 clinical trial of COVAXIN.
Preliminary results of Phase 1 clinical trials show that Bharat Biotech-ICMR's coronavirus vaccine 'Covaxin' is safe to use, principal investigators conducting the trials told ET.
A message is going viral on social media stating that the vaccine against COVID-19 produced by Bharat Biotech has received permission from the central government and will be available in the market from 15 August. The message is being shared with a letter from ICMR about fast-tracking the clinical trials of the vaccine.
Coronavirus vaccine is an urgency for the world as COVID-19 cases continue to rise with the United States, Brazil, and India sharing the top 3 positions in terms of maximum cases of the infectious disease. As all vaccines are currently under trial stage, a look at where some of the leading vaccines stand at this point in time.
The human clinical trial of indigenously developed Covaxin, a possible vaccine against the novel coronavirus, began at an institute here on Monday, a senior official said.
As the world is scrambling to develop a COVID-19 vaccine, Principal Investigator of vaccine trial team at Rohtak PGI Doctor Savita Verma informed that part 1 of phase-1 of Covaxin trial is completed and it shows encouraging results
India's first coronavirus vaccine — Covaxin — first part of phase 1 human trial has been completed at Post Graduate Institute (PGI) of Medical Sciences, Rohtak in Haryana.
Coronavirus vaccine trials have picked up pace across the globe. From UK's esteemed Oxford University to our very own Bharat Biotech, people have put in everything to find a shield immunity against COVID-19, a disease that has already infected over 15 million people worldwide.
Countries across the world are in the race to develop a vaccine, and many of them, including India, are conducting human clinical trials to test the efficacy. The phase-I human clinical trial of Covaxin, India's first indigenously-developed vaccine against coronavirus, began at the All India Institute of Medical Sciences (AIIMS) in Delhi today.
India’s COVID-19 vaccine COVAXIN has reached the human trials phase and Delhi’s AIIMS hospital is all set to vaccinate 5 volunteers today. COVAXIN has been indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
Chennai's SRM Medical Hospital has begun the first phase of human clinical trials of the indigenous COVID-19 vaccine.
The All India Institute of Medical Sciences (AIIMS), Delhi, on Monday began the process of recruiting volunteers for conducting human clinical trials of the indigenously developed COVID-19 vaccine candidate Covaxin, director Dr. Randeep Guleria said today
As part of human trials of Covaxin, India's first indigenous Covid-19 vaccine, two volunteers were given its first dose at the Nizam's Institute of Medical Sciences (NIMS) on Monday, doctors said.
Top News
Latest News
